Spring greetings! We hope this finds you staying healthy and enjoying some quality time with your family as we weather the coronavirus crisis. We certainly appreciate all the efforts of our medical personnel and first responders who work every day to help those in need while risking their own health and safety.
We hate to pile on with the doom and gloom, but this article describes the current situation and all the possible after-effects on such things as funding for charitable causes. Since asthma sufferers might be at increased risk if exposed to the virus, we are including links to some excellent webinars for all on practical treatment suggestions to those exposed to COVID-19. Meanwhile we remain hopeful about upcoming legislation at both the federal and state levels to address the specific needs of those living with severe allergies such as requiring training and awareness at restaurants.
As we hear more positive news about medications that work as well as vaccines, we will be sure to pass it on!
Now What? A Layman’s Appraisal of Covid-19…
…how it effects Allergy Advocacy and….well, everything else, too
By Jon Terry, founder April 14th, 2020
Greetings. At this time of international crisis, I sincerely hope all our readers are healthy and safe.
The coronavirus pandemic has impacted almost everyone around the globe. So many serious questions remain unanswered. How many lives will be lost? How many more individuals will become infected? How long will so many people need intensive medical care? When will the number of people at risk for COVID-19 begin to decline? (Who knows?)
It’s hard enough for those who have multiple food allergies to find products that are safe for them to eat, but with many grocery shelves now empty, the challenge is even greater. Read here about many families who are struggling to find the foods they know are safe due to the hoarding and stocking up by others. Please keep your fellow allergy sufferers in mind and only buy what you need. Food manufacturers are trying to keep up with the demand, and you may be able to buy directly from them if the need arises.
Like many Americans these days, Lisa M. Delmont is kept up at night by worry. But for Ms. Delmont, it’s the empty grocery store shelves that bring on dread.
Her 2-year-old son, Benjamin, is severely allergic to milk, eggs, cashews, pistachios and bananas, so she has to be judicious about the items she brings home. Exposure to the wrong food could send Benjamin into anaphylactic shock, something that has happened three times since he was born.
In this helpful article, researchers report that the large majority of people who experience recurrent anaphylaxis will suffer the exact same sequence of symptoms and reactions. So if one starts to experience symptoms of an allergic reaction, they will know to seek help immediately and administer an epinephrine auto-injector (EAI) device. Medical practitioners can teach their patients to recognize their unique symptoms to allow them to earlier identify anaphylaxis and administer therapeutic interventions.
In a study published in the Journal of Allergy and Clinical Immunology, researchers at the University of Toronto sought to determine whether people who suffered recurring anaphylaxis had a similar progression of symptoms each time.
They looked at records from patients seen at a tertiary care allergy clinic from 2012-2018 and analyzed the sequence of symptoms recorded from each patient. They included only the episodes of anaphylaxis to a single allergen, leaving records for 3,174 anaphylactic reactions in 162 patients. These patients ranged from 1-71 years of age with 77% being female.
By Trisha Korioth, Staff Writer AAP News March 25, 2020
The Food and Drug Administration (FDA) is warning that EpiPen 0.3 mg, EpiPen Jr. 0.15 mg and the authorized generic versions of the epinephrine products may have delayed injection or be prevented from proper injection.
The FDA urges people to inspect their epinephrine auto-injectors before a life-threatening emergency to make sure the blue safety release is not raised and that they can remove the device easily from the carrier tube.
Pfizer and Mylan issued a letter to health care providers on March 23 involving the brand and generic versions.